Prediction of response to medical therapy by serum soluble (pro)renin receptor levels in Graves’ disease

Mizuguchi, Yasuo; Morimoto, Satoshi; Kimura, Shihori; Takano, Noriyoshi; Yamashita, Kaoru; Seki, Yasufumi; Bokuda, Kanako; Yatabe, Midori; Yatabe, Junichi; Watanabe, Daisuke; Ando, Takashi; Ichihara, Atsuhiro

doi:10.1371/journal.pone.0195464

Cited by 7 publications

(5 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, higher ATP6AP2 expression was associated with greater IgA deposits and more severe phenotypes . Additionally, in Graves' disease, a thyroid‐specific autoimmune disease, ATP6AP2 has been reported to be a potential disease and therapeutic biomarker …”

Section: The Immunological Impact Of Glycosylation Defects—an Update mentioning

confidence: 99%

See 1 more Smart Citation

CDG and immune response: From bedside to bench and back

Pascoal

Francisco

Ferro

et al. 2019

J of Inher Metab Disea

View full text Add to dashboard Cite

Glycosylation is an essential biological process that adds structural and functional diversity to cells and molecules, participating in physiological processes such as immunity. The immune response is driven and modulated by protein‐attached glycans that mediate cell‐cell interactions, pathogen recognition and cell activation. Therefore, abnormal glycosylation can be associated with deranged immune responses. Within human diseases presenting immunological defects are congenital disorders of glycosylation (CDG), a family of around 130 rare and complex genetic diseases. In this review, we have identified 23 CDG with immunological involvement, characterized by an increased propensity to—often life‐threatening—infection. Inflammatory and autoimmune complications were found in 7 CDG types. CDG natural history(ies) and the mechanisms behind the immunological anomalies are still poorly understood. However, in some cases, alterations in pathogen recognition and intracellular signaling (eg, TGF‐β1, NFAT, and NF‐κB) have been suggested. Targeted therapies to restore immune defects are only available for PGM3‐CDG and SLC35C1‐CDG. Fostering research on glycoimmunology may elucidate the involved pathophysiological mechanisms and open new therapeutic avenues, thus improving CDG patients' quality of life.

show abstract

Section: The Immunological Impact Of Glycosylation Defects—an Update mentioning

confidence: 99%

“…187 Additionally, in Graves' disease, a thyroid-specific autoimmune disease, ATP6AP2 has been reported to be a potential disease and therapeutic biomarker. 188…”

Section: Atp6ap2-cdgmentioning

confidence: 99%

CDG and immune response: From bedside to bench and back

Pascoal

Francisco

Ferro

et al. 2019

J of Inher Metab Disea

View full text Add to dashboard Cite

show abstract

“…It has been shown that basal blood s(P)RR levels differ among reports with a tendency of blood s(P)RR levels to be high in older subjects [4,20], patients with heart failure [7], renal dysfunction [21], or Graves' disease [22], and pregnant women [23,24]. The reason of the alterations of these values may be due to the differences of the disease and conditions of the subjects [24].…”

Section: Serum S(p)rr Levelsmentioning

confidence: 99%

Association between serum soluble (pro)renin receptor level and worsening of cardiac function in hemodialysis patients: A prospective observational study

et al. 2020

Self Cite

View full text Add to dashboard Cite

The (pro)renin receptor ((P)RR) is cleaved to generate soluble (P)RR (s(P)RR), which reflects the status of the tissue renin-angiotensin system. Hemodialysis (HD) patients have a poor prognosis due to the increased prevalence of cardiovascular diseases. The present study aimed to investigate whether serum s(P)RR level is associated with the worsening of cardiac function in HD patients. A total of 258 maintenance HD patients were recruited and serum s(P)RR concentration was measured. Background factors in patients who survived (S group) and patients who died (D group) during the 12-month follow-up period and relationships between serum s(P)RR level and changes in cardiac function during the follow-up period in the S group were investigated. The median serum s(P)RR value at baseline was 29.8 ng/ml. Twenty-four patients died during the follow-up period. Cardiothoracic ratio, human atrial natriuretic peptide (hANP), brain natriuretic peptide (BNP), and E over e-prime were significantly higher in the D group. In the S group, changes in hANP or BNP were significantly greater in the higher serum s(P)RR group than in the lower serum s(P)RR group. High serum s(P)RR level was significantly correlated with changes in BNP, independent of other factors. High serum s(P)RR level was associated with increases in BNP, independent of other risk factors, suggesting that an increased expression of (P)RR may be associated with a progression of heart failure in HD patients and that serum s(P)RR concentration could be used as a biomarker for selecting patients requiring intensive care.

show abstract

“…The mechanisms behind resistance to ATS are poorly understood [8] [9]. The MDR-1 multidrug resistance gene, which is responsible for resistance to a wide variety of drugs in human cells, is potentially involved [10].…”

Section: Commentsmentioning

confidence: 99%

“…Recent studies demonstrated that low baseline thyroglobulin autoantibodies are associated with refractoriness of Graves' disease to ATD treatment [8] [9]. Therefore, they could serve as biomarkers to predict the failure of ATD treatment in such patients.…”

Section: Commentsmentioning

confidence: 99%

Resistance to Anti-Thyroid Drugs in Graves’ Disease: Clinical-Biological Characteristics and Alternative Therapy in Tropical Area

Diack¹,

Ndiaye²,

Sène³

et al. 2020

OJEMD

View full text Add to dashboard Cite

Background: Resistance to anti-thyroid drugs (ATDs) is a rare entity recently described. We report two African observations in the treatment of Graves' disease. Case 1: A 19-year-old Senegalese woman presented on admission with thyrotoxicosis syndrome associated with diffuse goitre and Grave's orbitopathy. TSH levels were low (0.005 mIU/ml; N = 0.27-4.20) and fT4 elevated (60 pmol/L; N = 12-22]. Combination therapy with propranolol (40 mg/day) and carbimazole (starting dose of 45 mg/day and increased to 60 mg/day) was initiated. In view of the persistence of symptoms despite good therapeutic compliance, carbimazole was replaced by methimazole with an initial starting dose of 40 mg/day, followed by 60 mg/day. Despite the change in therapy, clinical symptoms of thyrotoxicosis persisted, and fT4 levels remained elevated. The patient was diagnosed with resistance to ATDs in Graves' disease. Total thyroidectomy following 10 days of preoperative preparation with 1% Lugol's solution was performed successfully. Case 2: A 22-year-old woman was referred for continued management of Graves' disease with elevated thyroid-stimulating hormone receptor antibody (TRAb) levels (34 UI/mL; N < 1.75). Treatment included propranolol (80 mg/day) and carbimazole at an unusual dose of 80 mg/day. Combined therapy was clinically and biologically ineffective, with an fT4 level of 100 pmol/L [N: 12-22]. Upon admission, methimazole (40 mg/day) followed by propylthiouracil (800 mg/day) replaced carbimazole. Despite good patient compliance, the patient's symptoms remained unaltered and fT4 levels elevated. A total robot thyroidectomy using the right axillary approach was performed successfully after 10 days of preoperative preparation, including prednisone (40 mg/day

show abstract

Prediction of response to medical therapy by serum soluble (pro)renin receptor levels in Graves’ disease

Cited by 7 publications

References 30 publications

CDG and immune response: From bedside to bench and back

CDG and immune response: From bedside to bench and back

Association between serum soluble (pro)renin receptor level and worsening of cardiac function in hemodialysis patients: A prospective observational study

Resistance to Anti-Thyroid Drugs in Graves’ Disease: Clinical-Biological Characteristics and Alternative Therapy in Tropical Area

Contact Info

Product

Resources

About